NIDA Clinical Trials Network: New York Node

由John Rotrosen和Edward Nunes领导的NIDA CTN的纽约节点(NYN)代表着2010年 合并纽约和长岛节点，这两个节点自2000年和2001年以来一直是CTN的一部分， 分别进行了分析。这第四个竞争对手的续订应用程序建立在强大且成功的基础架构之上，以 管理临床试验，以及主流试验的创新和成功实施的跟踪记录 大多数SUD患者都能看到的医疗保健环境。我们提供几乎所有关键CTN的专业知识 RFA-DA-20-024中概述的优先事项，包括：将SUD治疗和预防纳入主流 环境(初级保健、急诊科、刑事司法)；利用电子健康记录 支持改善和扩大护理；开发药物和行为疗法；共同发生的医疗 和精神障碍；妇女和少数群体；数字和其他以技术为基础的干预；数据 科学，包括新的数据分析方法；以及实施科学、卫生经济学、宣传、 以及维持循证干预的政策。在新的资助期内，纽约银行将牵头或联合牵头 7个雄心勃勃的项目，全部计划于2019年或2020年开始：CTN-0079-A1采纳附属研究 ED引发的丁丙诺啡的安全性和可持续性；关于PrEP和阿片类药物使用的CTN-0082实施调查 性传播感染诊所和社区组织的相关服务；CTN-0094个人水平预测 阿片类药物使用障碍治疗结果的模型化；CTN-0096以文化为中心的OUD垫 促进为美国人服务的初级保健和成瘾治疗方案的实施 印度/阿拉斯加原住民；CTN-0097克服戒断症状，开始纳曲酮快速治疗(SWIFT)： 提高注射用纳曲酮治疗阿片类药物使用障碍的实际疗效CTN-0100优化 阿片使用障碍药物治疗的保留、持续时间和停用策略；和CTN-0101 阈值下阿片类药物使用障碍预防(STOP)试验。我们还将继续帮助开发新的试验 CTN，包括在兴奋剂依赖领域，并为CTN试验提供场地。 为了支持这一点，我们从以下方面建立了一个由研究人员、提供商和政策制定者组成的协作网络 学术界、以社区为基础的成瘾治疗计划、大型多方面的医疗保健系统，以及纽约 城市和州机构，都在全国最大和最多样化的大都市地区。我们已经建立了一个 在我们工作的基础上，通过深思熟虑、严格和 循序渐进的改进。我们对网络未来的愿景包括围绕解决差距而构建的工作 突出的是阿片类药物治疗级联、对兴奋剂依赖的干预、CTN的有效使用 支持广泛的非CTN研究的平台，并继续致力于培训新的 一代成瘾的临床研究人员。此外，我们与实施科学家、卫生部门 经济学家、倡导团体和政策专家，以最大限度地提高有效新干预措施的可持续性。

The New York Node (NYN) of the NIDA CTN, led by John Rotrosen and Edward Nunes, represents the 2010 merger of the New York and Long Island Nodes, which had been part of the CTN since 2000 and 2001, respectively. This fourth competing renewal application builds on both a strong and successful infrastructure to manage clinical trials, and a track record of innovation and successful implementation of trials in mainstream healthcare settings where most SUD patients are seen. We contribute expertise in virtually all key CTN priorities outlined in RFA-DA-20-024, including: integration of SUD treatment and prevention in mainstream settings (primary care, emergency departments, criminal justice); leveraging the electronic health record to support improved and expanded care; developing medications and behavioral therapies; co-occurring medical and psychiatric disorders; women and minorities; digital and other technology-based interventions; data science including novel data analytic approaches; and implementation science, health economics, advocacy, and policy to sustain evidence-based interventions. In the new funding period, the NYN will lead or co-lead seven ambitious projects, all scheduled to begin in 2019 or 2020: CTN-0079-A1 Ancillary Study of the Adoption and Sustainability of ED-Initiated Buprenorphine; CTN-0082 Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and Community Based Organizations; CTN-0094 Individual Level Predictive Modeling of Opioid Use Disorder Treatment Outcome; CTN-0096 Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives; CTN-0097 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder; CTN-0100 Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; and CTN-0101 Subthreshold Opioid Use Disorder Prevention (STOP) Trial. We will also continue to help develop new trials in CTN, including in the area of stimulant dependence, and to supply sites for CTN trials. To support this, we have built a network of collaborating researchers, providers, and policy makers from academia, community-based addiction treatment programs, large multifaceted healthcare systems, and NY City and State agencies, all in the nation’s largest and most diverse metropolitan area. We have established a track record of substantial contributions to the CTN, building on our work through deliberate, rigorous, and stepwise improvements. Our vision for the Network’s future includes work built around addressing gaps highlighted by the opioid treatment cascade, interventions for stimulant dependence, effective use of the CTN platform to enable a broad range of non-CTN studies, and a continued commitment to training a new generation of addictions clinical researchers. Further, we partner with implementation scientists, health economists, advocacy groups, and policy experts to maximize the sustainability of effective new interventions.